In patients with prostate cancer in situ, immune checkpoint inhibitors increase the number of tumor‐infiltrating Th1 cells; however, in patients with bone metastasis of prostate tumor, immune checkpoint inhibitors increase Th17 subsets but not Th1 due to the presence of TGF‐β.368. This evidence concerns the gene TGFB1 and neoplasm.